Accelerating Pediatric Drug Development: A 2022 Special Issue of Therapeutic Innovation & Regulatory Science
This pediatric special issue of TIRS propels us into the next phase of pediatric drug development focused on innovative trial designs, issues related to rare diseases and pregnant individuals, advances in pediatric formulation development, development of digital technologies in pediatric trials, an update on pediatric global networks, and a discussion of stakeholder engagement with a focus on health equity and the voices of the children and their families.
The Drug Safety eLearning Program provides the knowledge you need, from regulations and requirements through pre-market review and post-market monitoring.
Patient Engagement Certficate Program
There is an ever-expanding area of collaboration that is occurring among patients, patient organizations, industry, regulators, and governmental organizations to ensure that new drugs developed represent value to the patients they aim to treat, that patient access to innovations is accelerated, and that patient experience and outcomes are optimal.